Post-Menopausal Bleeding (PMB) - 10 Marks PG Answer

Definition

Incidence and Clinical Significance

• PMB is the presenting complaint in 90% of women with endometrial carcinoma
• 10-15% of women presenting with PMB are ultimately diagnosed with a malignancy (endometrial or cervical)
• The golden rule: "Postmenopausal bleeding is endometrial cancer until proven otherwise"

Etiology / Differential Diagnosis

Table: Causes of PMB (Berek & Novak's Gynecology)

Mnemonic: PALM-COEIN framework (adapted for postmenopausal)

• Polyp, Adenocarcinoma, Leiomyoma, Malignancy
• Coagulopathy, Ovulatory dysfunction, Endometrial (atrophy), Iatrogenic (HRT/tamoxifen), Not yet classified

Risk Factors for Malignancy in PMB

1. Obesity (excess peripheral estrogen conversion via aromatase)
2. Nulliparity
3. Late menopause (after age 52)
4. Diabetes mellitus and Hypertension (association with endometrial cancer)
5. Unopposed estrogen therapy (risk increased 4-8x)
6. Tamoxifen use - increases polyp formation and endometrial cancer risk
7. Estrogen-secreting ovarian tumors (granulosa cell tumor)
8. Lynch syndrome / HNPCC - hereditary risk

Clinical Evaluation

History

• Duration, amount, and character of bleeding
• HRT / tamoxifen use
• Coital bleeding (suggests cervical/vaginal lesion)
• Associated pelvic pain, pressure, or discharge
• Family history of gynecological cancers

Physical Examination

• General: obesity, signs of hypo- or hyperestrogenism
• Abdominal: hepatomegaly, ascites, lymphadenopathy (supraclavicular, inguinal)
• Speculum exam: inspect vulva, vaginal walls (atrophy - thin, pale, friable mucosa), cervix for lesions, polyps, or abnormal discharge
• Bimanual rectovaginal exam: uterine size/mobility, adnexal masses, parametrial induration, cul-de-sac nodularity
• Rectal exam: exclude rectal bleeding as source; assess parametria

Note: Any abnormal lesion on cervix or vagina must be biopsied immediately.

Investigations

Step 1 - Cervical Assessment

• Pap smear / cervical cytology: essential first step; however, only 30-50% of endometrial cancers show abnormal Pap results - it is an insensitive test for endometrial cancer
• Colposcopy + directed biopsy if abnormal cytology or visible cervical lesion

Step 2 - Endometrial Assessment

A. Transvaginal Ultrasonography (TVUS) - First-line imaging

• Measures endometrial thickness (ET)
• ET ≤ 4 mm: associated with low risk of endometrial malignancy; endometrial sampling may be deferred
• ET ≥ 5 mm: mandates endometrial sampling
• Some authors recommend a cutoff of 3 mm for even greater sensitivity
• TVUS is also useful for detecting polyps, fibroids, adnexal masses

A 2024 systematic review (PMID: 39127112) found that the optimal ET threshold for predicting endometrial cancer in postmenopausal women without bleeding remains uncertain, underscoring that clinical context must guide the threshold used.

B. Endometrial Biopsy (EMB) - Gold Standard First Step

• Office aspiration biopsy (Pipelle cannula) is the accepted first-line tissue sampling method
• Diagnostic accuracy: 90-98% compared to D&C or hysterectomy findings
• Obtains adequate tissue in >95% of cases
• Persistent / recurrent bleeding after negative biopsy mandates further workup (D&C / hysteroscopy)

C. Hysteroscopy + Directed Biopsy

• Gold standard for visualizing the endometrial cavity
• Superior to EMB or D&C for detecting polyps and submucosal fibroids
• Indicated when:
  • Cervical stenosis prevents adequate office biopsy
  • EMB is inadequate or inconclusive
  • Bleeding recurs after a negative biopsy
  • Sonohysterography reveals an intrauterine lesion

D. Dilatation and Curettage (D&C)

• Therapeutic as well as diagnostic
• Can miss focal lesions - hence hysteroscopy is preferred

E. Sonohysterography (SIS - Saline Infusion Sonography)

• Useful adjunct to TVUS
• Improves detection of focal lesions (polyps, submucous myoma)

Step 3 - Additional Investigations

• Blood tests: CBC, coagulation profile, liver function tests, serum CA-125 (if adnexal mass)
• Urine and stool testing to exclude non-genital sources of bleeding
• MRI pelvis: staging of confirmed endometrial malignancy
• CT chest/abdomen/pelvis: staging for suspected advanced or metastatic disease

Management

1. Atrophic Vaginitis / Endometritis

• Topical (vaginal) estrogen - cream, pessary, or ring; systemic absorption is minimal
• Provides significant quality-of-life improvement
• Contraindications must be evaluated; patient preference must be considered

2. Hormone Replacement Therapy (HRT)-Related Bleeding

• Endometrial sampling is indicated for any unexpected or unscheduled bleeding while on HRT
• Continuous low-dose combined HRT (estrogen + progestogen) - bleeding often ceases within a few months
• Missed doses should be addressed; non-oral routes (patches, gel) improve compliance
• Unopposed estrogen must never be used in women with intact uterus

3. Endometrial and Cervical Polyps

• Office polypectomy - cervical polyps can be removed in the outpatient setting
• Hysteroscopic polypectomy for endometrial polyps (especially in postmenopausal women, as polyps have a higher malignant potential in this age group)
• Hypertension is an independent risk factor for malignancy within a polyp

4. Endometrial Hyperplasia

• Progestins (medroxyprogesterone acetate, norethisterone, levonorgestrel-IUS): first-line for benign hyperplasia
• Total hysterectomy: preferred for EIN, especially in postmenopausal women who have completed childbearing

5. Endometrial Carcinoma

• Surgical staging (FIGO system): Total extrafascial hysterectomy + bilateral salpingo-oophorectomy + pelvic/para-aortic lymph node dissection
• Adjuvant radiotherapy and/or chemotherapy based on stage and grade
• Detailed management is covered separately under endometrial cancer

6. Tamoxifen-Related Endometrial Changes

• Increased surveillance with TVUS
• Any bleeding warrants endometrial sampling regardless of ET
• Hysteroscopic evaluation if polyps detected (higher malignant potential)

Algorithm / Diagnostic Flowchart

PMB (Any vaginal bleeding ≥12 months after LMP)
        |
        ↓
Pelvic exam + Pap smear
        |
        ├──→ Visible cervical/vaginal lesion → Biopsy/Colposcopy
        |
        ↓
Transvaginal Ultrasound (TVUS)
        |
        ├──→ ET ≤ 4 mm (low risk) + No focal lesion → Conservative; re-evaluate if bleeding recurs
        |
        ├──→ ET ≥ 5 mm OR focal lesion → Endometrial Biopsy (Pipelle)
                |
                ├──→ Adequate specimen, benign → Treat cause
                |
                ├──→ Inadequate / recurrent bleeding → Hysteroscopy + D&C
                |
                └──→ Malignancy / EIN → Further staging & management

Key Exam Points (PG Viva / Theory)

1. PMB is endometrial cancer until proven otherwise - even 1 episode of minimal bleeding warrants full evaluation
2. Endometrial atrophy is the single most common cause (60-80%), not cancer
3. TVUS ET ≤ 4 mm - safely excludes malignancy; sampling can be deferred
4. Pipelle biopsy has 90-98% diagnostic accuracy - first-line tissue sampling
5. Hysteroscopy is superior to D&C for focal lesions (polyps, submucosal fibroids)
6. 10% of PMB = malignancy - never underestimate
7. Uterine leiomyomas should never be accepted as a cause of PMB
8. Tamoxifen is a selective estrogen receptor modulator - acts as an estrogen agonist on endometrium - causes polyps and increases cancer risk
9. EIN (formerly complex hyperplasia with atypia) carries 29% risk of malignancy and should be managed with hysterectomy in postmenopausal women
10. A negative Pap smear does not exclude endometrial cancer

Pubertal Menorrhagia - 10 Marks PG Answer

Definition

Under the FIGO/ACOG PALM-COEIN classification (2012), heavy menstrual bleeding has replaced the older term "dysfunctional uterine bleeding" (DUB).

Physiology of the Perimenarchal Period

• After menarche, menstrual cycles remain anovulatory for an average of 18 months while the hypothalamic-pituitary-ovarian (HPO) axis matures
• Without ovulation, no corpus luteum forms → no progesterone secretion
• Unopposed estrogen causes continuous endometrial proliferation
• The endometrium eventually outgrows its blood supply and sheds irregularly, heavily, and unpredictably
• This is the physiological basis of anovulatory dysfunctional uterine bleeding (DUB) at puberty

Incidence

• Menorrhagia is one of the three most common presentations of abnormal vaginal bleeding in adolescents (along with anovulation and amenorrhea)
• Up to 24% of adolescents with menorrhagia may have an underlying undiagnosed bleeding disorder
• A 2024 systematic review and meta-analysis of 2,770 adolescent females (PMID: 38378571) found:
  • Ovarian/Uterine Disorders: 23.7%
  • Coagulation Disorders: 19.4%
  • Platelet Disorders: 6.23%
  • 45.9% of cases remained of indeterminate origin

Etiology / Causes

A. Non-Structural (Most Common)

B. Structural (Less Common in Adolescents)

Key concept: Hematological disorders are far more common in adolescent menorrhagia than in adult menorrhagia. vWD must be screened in every adolescent presenting with heavy menstrual bleeding at or near menarche.

Clinical Features

Presentation

• Heavy menstrual bleeding at/after menarche - soaking pads/tampons frequently, flooding, passing clots
• Prolonged bleeding (>7 days)
• Fatigue, pallor, dizziness (signs of anemia)
• School/activity disruption - a key clinical indicator of severity

Severity Classification (Berek & Novak's)

History Taking

1. Menstrual history: Age at menarche, cycle length, duration of flow, number of pads/tampons per day, passage of clots, flooding
2. Onset: Was the very first period heavy? (Strongly suggests bleeding disorder)
3. Systemic bleeding: Easy bruising, epistaxis, bleeding from dental extractions, post-surgical bleeding, family history of bleeding disorders
4. Medications: Anticoagulants, aspirin, hormonal therapy
5. Thyroid symptoms: Weight gain, cold intolerance, constipation (hypothyroidism)
6. Sexual activity: Confidential history; pregnancy must always be excluded
7. Weight: Obesity (peripheral aromatization), anorexia/extreme leanness (hypothalamic dysfunction)
8. Family history: Bleeding disorders, thyroid disease, PCOS

Validated tool: The Pictorial Blood Assessment Chart (PBAC) - a semi-quantitative tool to document blood loss objectively; score >100 per cycle = menorrhagia.

Investigations

Step 1 - Mandatory Baseline

Step 2 - Targeted Investigations

Step 3 - Imaging (Selected Cases)

Note: Endometrial biopsy is rarely indicated in adolescents. Pelvic examination itself should be deferred in virginal adolescents unless clinically necessary, and rectal examination may substitute for bimanual palpation.

Management

A. Acute/Severe Menorrhagia (Hb <10 g/dL or hemodynamic instability)

1. IV access + resuscitation - IV fluids, blood transfusion if Hb <8 g/dL or hemodynamically unstable
2. High-dose combined oral contraceptive pills (COCPs):
   • Monophasic pill (ethinyl estradiol 30-35 µg + progestin) - 1 tablet three to four times daily until bleeding stops (usually 24-48 hours), then taper to 1 tablet daily
   • Most commonly used acute medical therapy
3. Progestin-only therapy (if estrogen contraindicated):
   • Medroxyprogesterone acetate (MPA) 20 mg three times daily for 7 days (ACOG regimen)
4. Intravenous conjugated equine estrogens (25 mg IV q4-6h) for acute severe anovulatory bleeding - promotes rapid endometrial proliferation to halt bleeding
5. Tranexamic acid (antifibrinolytic): 1-1.5 g PO/IV three times daily - reduces blood loss, well tolerated; superior quality-of-life outcomes vs hormones and NSAIDs
6. Iron supplementation - oral ferrous sulfate or IV iron if severe deficiency
7. Hematology consultation - if coagulopathy or thrombocytopenia identified

B. Moderate Menorrhagia (Hb 10-12 g/dL)

1. Combined Oral Contraceptive Pills (first-line):
   • Monophasic COCP cyclically or continuously
   • Reduces blood loss by 35-69%
   • Additional benefits: cycle regulation, dysmenorrhea relief, acne improvement
   • Explain to parents: being used as medical therapy, not just contraception
2. Cyclic Progestins (if OCP declined/contraindicated):
   • MPA 5-10 mg/day for 10-13 days every 1-2 months (luteal phase supplementation)
   • Prevents endometrial hyperplasia from unopposed estrogen
3. NSAIDs (non-hormonal option):
   • Mefenamic acid 500 mg TID, naproxen 500 mg BD, or ibuprofen 400 mg q6h
   • Mechanism: inhibit COX → alter PGF₂α:PGE₂ ratio → vasoconstriction; also increase thromboxane A₂
   • Reduce blood loss by 20-50%; started on day 1 of menstruation
   • Less useful if structural pathology (fibroids)
4. Tranexamic acid (non-hormonal):
   • 500 mg-1.5 g TID during menses
   • Excellent safety profile in adolescents
5. Iron supplementation (all cases with anemia)

C. Mild Menorrhagia (Hb >12 g/dL)

• Reassurance - explain physiological basis (HPO axis maturation)
• Menstrual charting with PBAC diary
• Iron supplementation
• NSAIDs as needed for pain/flow control
• Close follow-up in 3-6 months

D. Specific Cause-Directed Management

E. Surgical / Invasive Management

• Hysteroscopy + directed biopsy/polypectomy: diagnostic and therapeutic for focal lesions
• Endometrial ablation: only in adolescents who do not desire future fertility and have failed medical therapy (very rare indication)
• Hysterectomy: extremely rare in adolescents; absolute last resort
• Uterine artery embolization: for bleeding caused by fibroids

F. Levonorgestrel-Releasing IUS (Mirena)

• Reduces blood loss by 71-95% - superior to COCPs (35-69%) and NSAIDs (10-52%)
• Alternative long-term therapy for adolescents who have failed or cannot tolerate other therapies
• Discuss in context of patient preference and comfort

Flowchart: Management Algorithm

Pubertal Menorrhagia (adolescent with HMB at/near menarche)
        |
        ↓
Assess severity → CBC, coagulation screen, pregnancy test, TFTs
        |
        ├──→ ACUTE (Hb <10, hemodynamic instability)
        │     → Admit + IV resuscitation
        │     → High-dose COCP / IV estrogens / Tranexamic acid
        │     → Blood transfusion if needed
        │     → Screen for coagulopathy
        |
        ├──→ MODERATE (Hb 10-12)
        │     → Outpatient: COCP cyclically
        │     → If COCP declined: Cyclic progestins or tranexamic acid
        │     → NSAIDs + Iron supplementation
        │     → Treat underlying cause (vWD, hypothyroidism)
        |
        └──→ MILD (Hb >12)
              → Reassurance + Iron
              → NSAIDs during menses
              → Menstrual diary + follow-up 3-6 months

Key Exam Points (PG Viva / Theory)

1. Most common cause of pubertal menorrhagia = anovulation due to HPO axis immaturity (immature positive estrogen feedback on LH surge)
2. HPO axis takes ~18 months after menarche to mature fully
3. 24% of adolescent menorrhagia may have an underlying bleeding disorder - always screen
4. vWD (von Willebrand Disease) = most common inherited coagulopathy causing menorrhagia; screen with vWF antigen + ristocetin cofactor assay
5. If first menstrual period is heavy - strongly suspect bleeding disorder
6. Pregnancy must be excluded in all cases before initiating hormonal therapy
7. Tranexamic acid - best quality-of-life outcomes; 71-95% reduction with LNG-IUS
8. Endometrial biopsy is NOT routinely indicated in adolescents
9. Pelvic examination may be deferred in virginal adolescents; transabdominal USG preferred
10. COCP is first-line for moderate anovulatory menorrhagia; cyclic progestins are the alternative
11. Hypothyroidism - menorrhagia resolves with levothyroxine; always check TSH
12. The PBAC score (>100 per cycle) is the standard objective measure of menorrhagia severity